12:49 , Mar 9, 2017 |  BC Week In Review  |  Clinical News

Rimiducid: Ph I BP-012 started

Bellicum began the open-label, U.S. Phase I BP-012 trial to evaluate BPX-601 plus rimiducid in up to 30 patients. Bellicum has rights to rimiducid from Ariad Pharmaceuticals Inc. under an amended 2006 deal (see BioCentury,...
12:49 , Mar 9, 2017 |  BC Week In Review  |  Clinical News

BPX-601: Ph I BP-012 started

Bellicum began the open-label, U.S. Phase I BP-012 trial to evaluate BPX-601 plus rimiducid (AP1903) in up to 30 patients. Bellicum has rights to rimiducid from Ariad Pharmaceuticals Inc. under an amended 2006 deal (see...
03:48 , Dec 10, 2016 |  BioCentury  |  Product Development

Rules of the road

Investigators and companies have long been devising strategies to mitigate or preempt toxicities from CAR T cell therapies without compromising efficacy. Now, data presented at the American Society of Hematology meeting suggest strategies to prevent...
21:56 , Dec 2, 2016 |  BioCentury  |  Product Development

CNS CAR crash?

Juno Therapeutics Inc. and other investigators in the CAR T field don’t know what caused fatal neurotoxicity in the Phase II ROCKET trial of CAR therapy JCAR015. But it appears the study’s CNS disease exclusion...
07:00 , Jul 18, 2016 |  BioCentury  |  Product Development

ROCKET resumes

The swift release of a clinical hold on Juno Therapeutics Inc.'s ROCKET trial notwithstanding, why and how high-dose fludarabine contributed to fatal neurotoxicity remains an unanswered - and important - question for the CAR T...